News

July 6, 2017

EU Approves Besponsa for Adults with B-Cell Acute Lymphoblastic Leukemia

ALL, News

The European Union has approved Pfizer‘s Besponsa as a treatment for adults with a type of B-cell leukemia. The authorization applies to patients with relapsed or refractory CD22-positive B-cell acute ... Read more

July 5, 2017

FDA Approves New Diagnostic Tool for Leukemias and Lymphomas

News

The U.S. Food and Drug Administration (FDA) has approved a new laboratory test to help clinicians detect leukemia and lymphoma cells using a technique called flow cytometry. The ClearLLab ... Read more

June 30, 2017June 30, 2017

85% of Hodgkin Lymphoma Patients Respond to Adcetris-Opdivo Combo, Trial Shows

News

A combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) led to Hodgkin lymphoma diminishing in 85 percent of patients in a Phase 1/2 trial (NCT02572167), researchers reported. Among them, ... Read more

June 29, 2017June 29, 2017

Adcetris-Chemotherapy Combo Lengthens the Time for Hodgkin’s Lymphoma to Progress, Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly lengthens the time it takes for Hodgkin’s lymphoma to progress, or for a patient to die, according to an updated of Phase 3 ... Read more

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. ... Read more

June 27, 2017June 27, 2017

FDA Approves Rituxan Hycela to Treat Two Lymphomas and One Type of Leukemia

News

Rituxan Hycela has received U.S. Food and Drug Administration approval as an injected treatment for two lymphomas and a type of leukemia, Genentech announced. The approval covers Rituxan Hycela’s use against relapsed ... Read more

June 26, 2017June 26, 2017

ADC Reports Positive Phase 1 Results on Antibody-drug Conjugate ADCT-301 for Hodgkin’s, NHL

News

Preliminary results from a Phase 1 trial testing ADC Therapeutics’ ADCT-301 to treat relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL) demonstrated the medication’s therapeutic potential with good overall response rates and ... Read more

June 23, 2017June 23, 2017

Truxima Shows Similar Safety and Efficacy Results to Rituxan in Phase 3 Trial

News

Results from a Phase 3 trial have shown that Truxima (CT-P10), developed by Celltrion Healthcare, has a similar efficacy and safety profile as Genetech’s Rituxan (rituximab) for the treatment of advanced-stage follicular ... Read more

June 22, 2017

At Least Four-fifths of Leukemia and Lymphoma Patients Respond to TRG-1202 Combo Therapy, Researchers Report

News

Ninety-four percent of patients with chronic lymphocytic leukemia and 79 percent with mantle cell lymphoma responded to treatment with a combination of TGR-1202 (umbralisib), Imbruvica (ibrutinib), and TG-1101, according to updated ... Read more

June 21, 2017

Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients

News

Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental ... Read more